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INTRODUCTION: This study protocol describes a trial designed to investigate
whether high-flow heated and humidified nasal oxygen (HFHO) therapy in patients
with hypercapnic acute respiratory failure (ARF) reduces the need of non-invasive
ventilation (NIV).
METHODS AND ANALYSIS: This is an open-label, superiority, international,
parallel-group, multicentre randomised controlled two-arm trial, with an internal
feasibility pilot phase. 242 patients with hypercapnic ARF requiring NIV admitted
to an intensive care unit, an intermediate care or a respiratory care unit will be
randomised in a 1:1 ratio to receive HFHO or standard oxygen in between NIV
sessions. Randomisation will be centralised and stratified by centre and pH at
admission (pH ≤7.25 or >7.25). The primary outcome will be the number of
ventilator-free days (VFDs) and alive at day 28 postrandomisation. The secondary
outcomes will encompass parameters related to the VFDs, comfort and tolerance
variables, hospital length of stay and mortality. VFDs at 28 days postrandomisation
will be compared between the two groups by Wilcoxon-Mann-Whitney two-sample
rank-sum test in the intention-to-treat population. A sensitivity analysis will be
conducted in the population of patients for whom the criteria of switching from NIV
to spontaneous breathing, or conversely, are not strictly verified.
ETHICS AND DISSEMINATION: The protocol has been approved by the (CPP) (ref
CPP17-049a/2017-A01830-53) and will be carried out in accordance with the
Declaration of Helsinki and Good Clinical Practice guidelines. A trial steering
committee will oversee the progress of the study. Findings will be disseminated
through national and international scientific conferences, and publication in peer-
reviewed journals.
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